It is recommended that metformin and sodium-glucose cotransporter 2 inhibitors should be discontinued in diabetic patients with severe COVID-19 disease to reduce their risk of developing lactic acidosis or diabetic ketoacidosis, respectively [64]. The gene discussed is SLC5A2; the disease is diabetic ketoacidosis.